ArticleMolecular cancer therapeutics2021
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026Review
- Resveratrol as a Dual MAPK/STAT3 Inhibitor in Glioblastoma: Mutation-Dependent Therapeutic Efficacy.Life (Basel, Switzerland) · 2026Article
- Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.Blood advances · 2026Article
- Clinical relevance of the somatic mutational landscaping in predicting outcome of bladder cancer patients.Scientific reports · 2025Article
- Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.International journal of molecular sciences · 2025Review
- Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors.BJC reports · 2024Article
- The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.Nature reviews. Cancer · 2024Review
- Chemotherapy-free treatment targeting fusions and driver mutations inTherapeutic advances in medical oncology · 2024Article
- Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.Journal of molecular biology · 2022Review
- Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma.Journal of clinical medicine · 2022Review
- BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
BRAF and MEK inhibitors are standard of care for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.